Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Pancreatic Neoplasms 8 Liver Neoplasms 5 Carcinoma, Hepatocellular 4 Lung Neoplasms 3 Squamous Intraepithelial Lesions 2 Prostatic Neoplasms 2 Uterine Cervical Neoplasms 1 Uterine Cervical Dysplasia 1 Urinary Bladder Neoplasms 1 Ureteral Neoplasms 1 Unresectable Pancreatic Cancer 1 Triple Negative Breast Neoplasms 1 Stomach Neoplasms 1 Small Cell Lung Carcinoma 1 Skin Neoplasms 1 Rectal Neoplasms 1 Pancreatic Ductal Adenocarcinoma 1 Neoplasm Metastasis 1 Melanoma 1 Lymphatic Metastasis 1 Liver, Cancer of, Non-Resectable 1 Laryngeal Neoplasms 1 Hilus Pulmonary Neoplasms 1 Head and Neck Neoplasms 1 HIV Seropositivity 1 Gallbladder Neoplasms 1 Extremities Neoplasms 1 Esophageal Neoplasms 1 Colorectal Liver Metastases 1 Carcinoma, Renal Cell 1

Interventions

Carboplatin 41 Paclitaxel 40 pembrolizumab 38 Cyclophosphamide 23 Gemcitabine 22 130-nm albumin-bound paclitaxel 21 Doxorubicin 18 Cisplatin 18 Albumin-Bound Paclitaxel 18 atezolizumab 16 Taxes 15 Capecitabine 13 veliparib 10 Nivolumab 9 Docetaxel 9 Bevacizumab 9 olaparib 8 liposomal doxorubicin 7 Everolimus 7 spartalizumab 6 durvalumab 6 Epirubicin 6 trametinib 5 pegfilgrastim 5 eribulin 5 Irinotecan 5 Filgrastim 5 iniparib 4 binimetinib 4 apatinib 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Triple Negative Breast Neoplasms × Electroporation × Clear all

NCT02531425 2023-05-15

TNBC

OncoSec Medical Incorporated

Phase 1 Completed

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡